Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, announced it has received CE Mark for Ortho's VITROS® XT MicroSlide, a new multi-test technology that allows labs to run two tests simultaneously.
A study published today in the journal Nature provides a deeper understanding of why pancreatic cancer spread, or metastasis, is most commonly found in the liver.
Just 12 months after opening its doors, New U Life announced it sold more than 500,000 bottles of its innovative SOMADERM Gel in 2018. Hitting this significant milestone reflects the passion of its hardworking distributors and the leadership of Founder and Formulator Alexy Goldstein.
Merck, a leading science and technology company and leader in genome editing, today announced that the Canadian Patent Office has allowed Merck's patent application directed to the use of paired CRISPR nickases in eukaryotic cells.
Pangea® Laboratory announced today the licensing of a new urine-based Laboratory Developed Test (LDT) for bladder cancer detection. Commercialized and sold under the name Bladder CARE™, the test is non-invasive, cost-effective and epigenetic-based.
TC BioPharm (TCB) today announced it is collaborating with Dublin's Trinity College to accelerate in-house production of V delta 1 γδ T cell banks for treatment of solid tumors.
Terumo Cardiovascular Group, a global leader in cardiovascular surgery technologies, and Hemostasis, LLC., today announced a three-year exclusive distribution agreement that will bring BoneSeal® bone hemostat to the United States cardiac surgery market.
Aphena Pharma Solutions Inc. has announced the expansion of its blister packaging capacity with the purchase of a PharmaWorks TF2 blister packaging line with in-line cartoning capabilities, supplementing its recent vault enlargement to handle emerging requirements for DEA-controlled products.
Baxter International Inc. (NYSE:BAX), a global innovator in renal care, announced today that the first patients have been enrolled in a U.S. clinical trial for the company’s on-demand peritoneal dialysis (PD) solution generation system.
Adaptive Biotechnologies, an immune-driven medicine company, today announced that it will enter into a worldwide collaboration and license agreement with Genentech, a member of the Roche Group, to develop, manufacture and commercialize novel neoantigen directed T-cell therapies for the treatment of a broad range of cancers.